President Barack Obama is calling for an investment to move away from one-size-fits-all-medicine, toward an approach that tailors treatment to your genes. The White House said Friday that Obama will ask Congress for $215 million for what he's calling a precision medicine initiative. The ambitious goal: Scientists will assemble databases of about a million volunteers to study their genetics to learn how to individualize care.
In the midst of a worrisome flu season, health officials are pushing doctors to prescribe...
The flu is now widespread in all but seven states, and hospitalization rates match the dismal...
The next Ebola or the next SARS. Maybe even the next HIV. Even before the Ebola epidemic in West Africa is brought under control, public health officials are girding for the next health disaster. Ebola sprang from one of those blind spots, in an area that lacks the health systems needed to detect an outbreak before it becomes a crisis.
U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking such safeguards. The FDA approved Purdue Pharma's Hysingla ER for patients with severe, round-the-clock pain that cannot be managed with other treatments.
The government proposed new rules Wednesday to make it easier for doctors and patients to learn if clinical trials of treatments worked or not. Thousands of Americans participate in clinical trials every year, testing new treatments, comparing old ones or helping to uncover general knowledge about health. Many of the studies are reported in scientific journals and trumpeted in the news.
Millions of people with stents that prop open clogged heart arteries may need anti-clotting drugs much longer than the one year doctors recommend now. A large study found that continuing for another 18 months lowers the risk of heart attacks, clots and other problems. Even quitting after 30 months made a heart attack more likely, raising a question of when it's ever safe to stop.
Nanomedicine is offering patients a growing arsenal of therapeutic drugs for a variety of diseases, but often at a cost of thousands of dollars a month. Generics could substantially reduce the price tag for patients—if only there were a well-defined way to make and regulate them. An article in Chemical & Engineering News (C&EN) details the challenges on the road to generic nanodrugs.
Health workers on the front line of the Ebola crisis say the need for urgent help isn't letting up, as Congress begins considering President Barack Obama's $6.2 billion emergency aid request to fight the disease. Despite reports that the number of infections is slowing in some parts of West Africa, cases still are rising in other areas.
Medicare may soon begin paying for yearly scans to detect lung cancer in certain current or former heavy smokers. The Centers for Medicare and Medicaid Services on Monday issued a long-awaited proposal to begin covering the screening for high-risk beneficiaries if their doctors agree they meet the criteria.
Dr. Robert Fuller didn't hesitate to go to Indonesia to treat survivors of the 2004 tsunami, to Haiti to help after the 2010 earthquake or to the Philippines after a devastating typhoon last year. But he's given up on going to West Africa to care for Ebola patients this winter. He could make the six-week commitment sought by his go-to aid organization, International Medical Corps.
Top medical experts studying the spread of Ebola say the public should expect more cases to emerge in the U.S. by year's end as infected people arrive here from West Africa, including American doctors and nurses returning from the hot zone and people fleeing from the deadly disease. But how many cases?
U.S. health officials are recommending that people who are at highest risk for coming down with Ebola avoid commercial travel or attending large public gatherings, even if they have no symptoms. The Centers for Disease Control and Prevention issued the updated advice to state and local officials on Monday.
The governors of New York and New Jersey are at odds with scientists over Ebola as they back 21-day quarantines for medical workers returning from West Africa, while the nation's top infectious-disease expert warns that such restrictions are unnecessary and could discourage volunteers from aiding disease-ravaged countries.
The federal government is closing a gap in Ebola screening at airports while states from New York to Texas to California work to get hospitals and nurses ready in case another patient turns up somewhere in the U.S. with the deadly disease. Under the rule going into effect Wednesday, air travelers from the West African nations must enter the U.S. through one of five airports doing special screenings and fever checks for Ebola.
President Barack Obama urged his top national security and public health officials on Monday to incorporate lessons from the most recent Texas Ebola infection into the U.S.'s response plans to the deadly virus. He also called on the international community to deliver assistance more quickly to the countries of West Africa that are struggling against the disease.
The American strategy on Ebola is two-pronged: step up desperately needed aid to West Africa and, in an unusual step, train U.S. doctors and nurses for volunteer duty in the outbreak zone. At home, the goal is to speed up medical research and put hospitals on alert should an infected traveler arrive.
DARPA’s new Electrical Prescriptions (ElectRx) program was among the initiatives the White House highlighted this week as President Barack Obama addressed the need for new and more effective strategies for improving the health of service members, veterans and others. ElectRx goes beyond medication, aiming to explore neuromodulation of organ functions to help the human body heal itself.
A number of leading international researchers, among others from the National Food Institute, Technical University of Denmark, have recommended that fluorochemicals should only be used where absolutely essential, until better methods exist to measure the chemicals and more is known about their potentially harmful effects.
Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease. The Indianapolis-based company announced initial results from the research on Thursday and said it plans to submit the drug, ixekizumab, to regulators in the first half of next year.
British drugmaker AstraZeneca says the U.S. Dept. of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action. The company announced in October 2013 that federal officials were looking into the 18,000-patient study, which began in 2009.
A federal panel says older Americans should start getting a new vaccine against bacteria that cause pneumonia. The Advisory Committee on Immunization Practices voted Wednesday to recommend a dose of the expensive new shot for people 65 and older. The panel said older adults should still get an older pneumococcal vaccine, too.
The Food and Drug Administration has approved the first screening test for colon cancer that uses patient DNA to help spot potentially deadly tumors and growths. The Cologuard test from Exact Sciences detects irregular mutations in a patient's stool sample that can be an early warning sign of cancer. Patients who test positive for the mutations should undergo a colonoscopy to confirm the results.
The use of an experimental drug to treat two Americans diagnosed with Ebola is raising ethical questions about who gets first access to unproven new therapies for the deadly disease. But some health experts fear debate over extremely limited doses will distract from tried-and-true measures to curb the growing outbreak.
A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than three million Americans. In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined, according to new data from IMS Health.
Veterans, medical marijuana activists and scientists welcomed the first federally approved research into pot as a treatment for post-traumatic stress disorder. But their hopes for the research were dashed when the Univ. of Arizona fired researcher Suzanne Sisley, who undertook the study after clearing four years of bureaucratic hurdles.
According to recent research in the U.K. , use of electronic health records to understand the best available treatment for patients, from a range of possible options, is more efficient and less costly for taxpayers than the existing clinical trial process.
Imagine a low-cost treatment for a life-threatening infection that could cure up to 90% of patients with minimal side effects, often in a few days.It may sound like a miracle drug, but this cutting-edge treatment is profoundly simple—though somewhat icky: take the stool of healthy patients to cure those with hard-to-treat intestinal infections.
- Page 1